New blood tests could sharpen CMV monitoring in transplant patients
NCT ID NCT07286461
First seen Jan 03, 2026 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This study looks at whether measuring two new viral markers (CMV-RNA and TTV-DNA) in the blood can give a clearer picture of CMV infection in patients who have had a stem cell transplant and are taking the drug letermovir to prevent CMV. Researchers will track 290 adult transplant recipients to see if these markers predict when CMV reactivates or when anti-CMV treatment is needed. The goal is to improve monitoring and reduce unnecessary treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heinrich-Heine-Universitaet Duesseldorf
Düsseldorf, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
letermovir prophylaxis
What this could lead to
If successful, this could lead to more accurate monitoring of CMV infection in transplant patients, potentially reducing unnecessary treatments and improving outcomes.
What could go wrong
This is an observational study, not a treatment trial. The markers being tested may not prove reliable enough to change current practice. Results are exploratory and need further validation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.